Evidence digest
What the research on VIP actually shows
The indexed literature on VIP includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether VIP is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for VIP (4).
- Published research is indexed back to 1970, with roughly 15,132 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether VIP is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
2 human — controlled trial · 1 case report · 1 systematic review
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trialThe Lancet. Respiratory medicine · 2023 | Human — controlled trial | Not recorded | — | There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligi… | PMID 37348524 |
| Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal PeptideCritical care explorations · 2022 | Case report | Not recorded | — | Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broad array of injuries by binding to the vasoactive intestinal peptide receptor 1 receptor of alveolar type II cells, the cells that severe acute respiratory syndrome coronavirus 2 binds to. As the role of Aviptadil in treating pregnant patients … | PMID 35018346 |
| The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled TrialCritical care medicine · 2022 | Human — controlled trial | Not recorded | — | Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 r… | PMID 36044317 |
| Erectile dysfunction: a global review of intracavernosal injectablesWorld journal of urology · 2019 | Systematic review | Not recorded | — | Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice. A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluat… | PMID 30895359 |
Vendors listing VIP
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Next Gen Peptides | 93.897% | 1 | profile → |
| PeptidePlugs | 89.790% | 1 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.